Dapagliflozin, a highly regarded therapeutic drug targeting proximal tubules, is a selective inhibitor of SGLT2 and significantly slows the progression of kidney disease in type 2 diabetic patients [13]. The gene discussed is SLC5A2; the disease is kidney disorder.